Modality
Cell Therapy
MOA
SOS1i
Target
JAK2
Pathway
Complement
MCCCrohn'sUC
Development Pipeline
Preclinical
~Jun 2013
→ ~Sep 2014
Phase 1
~Dec 2014
→ ~Mar 2016
Phase 2
~Jun 2016
→ ~Sep 2017
Phase 3
Dec 2017
→ May 2030
Phase 3Current
NCT04588850
1,507 pts·Crohn's
2021-09→2030-05·Recruiting
NCT08234718
2,822 pts·MCC
2017-12→2027-04·Recruiting
NCT08529373
2,856 pts·UC
2017-12→2026-10·Active
+1 more trial
9,602 total pts3 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (6)
2025-07-139mo agoNDA· Crohn's
2026-03-064w agoPh3 Readout· Crohn's
2026-05-021mo awayBTD· MCC
2026-10-227mo awayPh3 Readout· UC
2027-04-211.1y awayPh3 Readout· MCC
2030-05-124.1y awayPh3 Readout· Crohn's
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P3
Recruit…
P3
Active
P3
Recruit…
P3
Complet…
Catalysts
NDA
2025-07-13 · 9mo ago
Crohn's
Ph3 Readout
2026-03-06 · 4w ago
Crohn's
BTD
2026-05-02 · 1mo away
MCC
Ph3 Readout
2026-10-22 · 7mo away
UC
Ph3 Readout
2027-04-21 · 1.1y away
MCC
Ph3 Readout
2030-05-12 · 4.1y away
Crohn's
RecruitingActiveCompleted|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04588850 | Phase 3 | Crohn's | Recruiting | 1507 | Mayo |
| NCT08234718 | Phase 3 | MCC | Recruiting | 2822 | ORR |
| NCT08529373 | Phase 3 | UC | Active | 2856 | OS |
| NCT04643118 | Phase 3 | Crohn's | Completed | 2417 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| HAL-1232 | Halozyme | Approved | C5 |